People on the blockbuster weight-loss and diabetes drugs Wegovy and Ozempic may be at higher risk of one-eye blindness from a rare eye condition, new research finds. The study, published in the journal JAMA Ophthalmology, included the medical records of about 17,000 people over six years. It found that patients with diabetes who were prescribed semaglutide, which is marketed as Wegovy and Ozempic, were about four times more likely to be diagnosed with non-arteritic anterior ischemic optic neuropathy (NAION), an eye condition that is painless but cannot be treated or cured. Meanwhile, overweigh…